An insightful article from The Medicine Maker highlights China's rapidly growing role in global biopharmaceutical innovation.
What interests us most isn't which country leads, but what this means for patients around the world.
As promising new therapies emerge across borders, access alone isn't enough. Patients need reliable information, careful evaluation of clinical evidence, trusted medical partners, and guidance through increasingly complex healthcare choices.
At Kaiyan Global Health, we believe the future of healthcare is not limited by geography — but it must always be guided by evidence, safety, and patient needs.
Innovation is global. Patient care should be, too.
Source: America Votes, China Plans — China sets out its stall for global biopharmaceutical preeminence as the US faces further uncertainty over research funding and regulation. Read the article